Stay up to date on practice-changing data in community practice.
Newer Trials Explore High-Risk Treatment and MRD in Multiple Myeloma
During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials of frontline therapy in multiple myeloma.
Read More
Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM
In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.
Listen
Daratumumab Plus VMP Shows Sustained Benefit in Transplant-Ineligible Myeloma
The final ALCYONE analysis with 86.7-month follow-up shows daratumumab-VMP significantly improved overall survival in transplant-ineligible, newly diagnosed multiple myeloma.
Advancing Myeloma Treatment With Blood-Based MRD Testing
In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
Talquetamab Shows Promise for High-Risk Relapsed/Refractory Myeloma
During a live event, Naresh Bumma, MD, discussed talquetamab’s efficacy in relapsed/refractory multiple myeloma, including high-risk patients.
Optimizing CAR T-Cell Therapy Prep in Multiple Myeloma After Relapse
During a live event, Jack Khouri, MD, discussed options for patients with multiple myeloma after relapse and choices to consider before CAR T-cell therapy.
